Skip to main content
Aptamer Sciences Inc logo

Aptamer Sciences Inc — Investor Relations & Filings

Ticker · 291650 ISIN · KR7291650000 KO Manufacturing
Open in API
Filings indexed 230 across all filing types
Latest filing 2024-10-25 Regulatory Filings
Country KR South Korea
Listing KO 291650

About Aptamer Sciences Inc

https://aptsci.com/en/

Aptamer Sciences Inc. is a clinical-stage biopharmaceutical company specializing in aptamer technology. The company has established a proprietary, integrated platform for the discovery and development of aptamer-based therapeutics and diagnostics. Its primary focus is on oncology, utilizing its Aptamer-Drug Conjugate (ApDC™) platform to create targeted cancer treatments. The lead candidate, AST-201, is an ApDC targeting the GPC3 protein, which is highly expressed in solid tumors such as liver cancer. The company is advancing AST-201 through clinical trials to evaluate its safety and efficacy. The development pipeline also includes other innovative platforms like Aptamer Radioligand Conjugates (ApRC) and Aptamer Immune Stimulator Conjugates (ApIS), aimed at addressing unmet medical needs in hemato-oncology and other areas. Aptamer Sciences leverages its technology to develop novel therapies with the potential for high specificity and efficacy.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험계획승인신청등결정) (압타머-약물접합체(ApDC) 고형암 치료제 AST-201의 국내 제1상 임상시험계획(IND) 승인)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from Aptamer Science regarding the approval of a Phase 1 clinical trial (IND) for their drug candidate AST-201 by the Korean Ministry of Food and Drug Safety (MFDS). This is a specific corporate disclosure regarding material business developments (clinical trial status). Since it does not fit into specific categories like financial reports, dividends, or management changes, and is a formal regulatory disclosure filed with the exchange, it falls under the 'Regulatory Filings' category.
2024-10-25 Korean
[기재정정]증권신고서(지분증권) (2024.11)
Capital/Financing Update Classification · 1% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) filed by Aptamer Science. It details amendments to a previously filed securities registration statement, including updates to public offering schedules, risk factors, and business development status. In the context of financial filings, a Securities Registration Statement (and its amendments) is a regulatory document required for capital raising activities, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 10-K, IR, or ER.
2024-10-22 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a formal regulatory disclosure regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) by Aptamer Sciences. It details the contract value, counterparty, duration, and payment terms. Since this is a specific regulatory announcement of a material business event that does not fit into categories like financial reports, dividends, or management changes, it falls under the general regulatory filing category.
2024-10-21 Korean
임원ㆍ주요주주특정증권등거래계획보고서
Major Shareholding Notification Classification · 1% confidence The document is a 'Report on Trading Plan for Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 거래계획보고서) filed by Aptamer Science. This is a specific regulatory filing required by the Financial Services Commission and the Korea Exchange in South Korea when insiders plan to trade their company's securities. Since it does not fit into standard categories like 'Director's Dealing' (which is for completed trades) or 'Major Shareholding Notification' (which is for threshold crossings), and it is a formal regulatory disclosure, it is best classified as a Regulatory Filing (RNS).
2024-10-18 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 1% confidence The document is an official regulatory filing from Aptamer Science regarding the acquisition of convertible bonds before maturity. It details the specific bond series, the amount acquired, the reason for acquisition (early redemption), and the method of cancellation. This falls under capital structure changes and financing updates, specifically related to debt instruments.
2024-10-07 Korean
[기재정정]증권신고서(지분증권) (2024.11)
Capital/Financing Update Classification · 1% confidence The document is a '증권신고서(지분증권) 정정신고' (Amendment to Securities Registration Statement) filed by Aptamer Science. It details specific amendments to a previously filed securities registration statement, including updates to the offering schedule, risk factors, and business descriptions. This is a formal regulatory filing required by the Financial Supervisory Service (FSS) in South Korea for companies conducting public offerings or capital raises. It fits the definition of a regulatory filing related to capital changes and securities registration.
2024-10-07 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.